Cardiovascular disease and osteoporosis: Is there a link between lipids and bone?

Annals of Clinical Biochemistry

Volumn 39, Issue 3, 2002, Pages 203-210

  Burnett, J R ^a,b   Vasikaran, S D ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; CERIVASTATIN; CHOLESTEROL; CLODRONIC ACID; COMPACTIN; ETIDRONIC ACID; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; INCADRONIC ACID; LIPID; MEVALONIC ACID; MEVINOLIN; MINODRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PITAVASTATIN; PRAVASTATIN; RISEDRONIC ACID; ROSUVASTATIN; SIMVASTATIN; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

BONE AND BONES; CALCINOSIS; CALCIUM; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIPHOSPHONATES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; OSTEOPOROSIS;

EID: 0036264588     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563021902134     Document Type: Review

References (60)

1. World-wide projections for hip fracture
2. Aortic calcification as a predictor of cardiovascular mortality
3. Osteoporosis and calcification of the aorta
4. Progression of aortic calcification is associated with metacarpal bone loss during menopause. A population-based longitudinal study
5. Atherosclerosis - An inflammatory disease
6. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography
7. Low-density lipoprotein-independent effects of statins
8. Cholesterol, endothelial function and cardiovascular disease
9. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
10. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol
11. Stimulation of bone formation in vitro and in rodents by statins
12. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
13. HMG-CoA reductase inhibitors and the risk of fractures
14. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
15. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
16. Mechanisms of action of bisphosphonates
17. Structural requirements for bisphosphonate actions in vitro
18. The pharmacology of bisphosphonates and new insights into their mechanisms of action
19. Cellular and molecular mechanisms of action of bisphosphonates
20. Clinical utility of biochemical markers of bone remodeling
21. Increased bone turnover in late menopausal women is a major determinant of osteoporosis
22. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate
23. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
24. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras
25. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis
26. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism
27. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
28. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
29. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro
30. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes
31. The biology of HMG-CoA reductase: The pros of contra-regulation
32. HMG-CoA reductase inhibitors: A look back and a look ahead
33. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion
34. Role of cholesterol in regulating apolipoprotein B secretion by the liver
35. New evidence for beneficial effects of statins unrelated to lipid lowering
36. Protein lipidation in cell signaling
37. Statins as a newly recognized type of immunosuppressor
38. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells
39. Statins and bone formation
40. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts
41. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells
42. Oral statins and increased bone-mineral density in postmenopausal women
43. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes
44. Statin drugs and the risk of fracture
45. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial
46. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized controlled trial
47. The effect of fluvastatin on parameters of bone remodeling
48. Effects of statins on biomarkers of bone metabolism: A randomised trial
49. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia
50. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
51. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis, a randomized double-masked prospective study using three dose levels
52. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report
53. Consequences of long-term hormone replacement
54. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study
55. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
56. The effect of disodium ethane-1-hydroxy-1,1-diphosphate (EHDP) on a rabbit model of athero-arteriosclerosis
57. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
58. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
59. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
60. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels